United Therapeutics Corporation – NASDAQ:UTHR
Founder-led company
United Therapeutics stock price today
$313.22
-46.73
-12.98%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 14 hours
United Therapeutics stock price monthly change
+12.00%
month
United Therapeutics stock price quarterly change
+12.00%
quarter
United Therapeutics stock price yearly change
+67.52%
year
United Therapeutics key metrics
Market Cap | 16.07B |
Enterprise value | 10.13B |
P/E | 15.47 |
EV/Sales | 5.23 |
EV/EBITDA | 9.79 |
Price/Sales | 5.31 |
Price/Book | 2.14 |
PEG ratio | 0.30 |
EPS | 22.38 |
Revenue | 2.49B |
EBITDA | 1.46B |
Income | 1.05B |
Revenue Q/Q | 33.69% |
Revenue Y/Y | 26.09% |
Profit margin | 37.56% |
Oper. margin | 50.6% |
Gross margin | 92.17% |
EBIT margin | 50.6% |
EBITDA margin | 58.78% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeUnited Therapeutics stock price history
United Therapeutics stock forecast
United Therapeutics financial statements
Average Price Target
$458
Potential upside: 46.22%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 596.5M | 259.2M | 43.45% |
|---|---|---|---|
| Sep 2023 | 609.4M | 267.6M | 43.91% |
| Dec 2023 | 614.7M | 217.1M | 35.32% |
| Mar 2024 | 677.7M | 306.6M | 45.24% |
| Jun 2023 | 6681300000 | 1.27B | 19.01% |
|---|---|---|---|
| Sep 2023 | 7023600000 | 1.31B | 18.67% |
| Dec 2023 | 7167000000 | 1.18B | 16.5% |
| Mar 2024 | 6495200000 | 1.15B | 17.81% |
| Jun 2023 | 106.3M | -227.2M | 24.7M |
|---|---|---|---|
| Sep 2023 | 346.2M | -313.4M | 7.6M |
| Dec 2023 | 150.7M | 42.1M | -92.8M |
| Mar 2024 | 376.5M | 735.3M | -1.06B |
United Therapeutics alternative data
| Aug 2023 | 985 |
|---|---|
| Sep 2023 | 985 |
| Oct 2023 | 985 |
| Nov 2023 | 985 |
| Dec 2023 | 985 |
| Jan 2024 | 985 |
| Feb 2024 | 985 |
| Mar 2024 | 1,168 |
| Apr 2024 | 1,168 |
| May 2024 | 1,168 |
| Jun 2024 | 1,168 |
| Jul 2024 | 1,168 |
United Therapeutics other data
84.33%
-5.56%
of UTHR is owned by hedge funds
412
-48
40.56M
-2.31M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2024 | 0 | 14400 |
| May 2024 | 0 | 115070 |
| Jun 2024 | 0 | 21600 |
| Nov 2024 | 0 | 60555 |
| Dec 2024 | 0 | 27700 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | BENKOWITZ MICHAEL officer: PRESIDEN.. | Stock Options | 2,500 | $111 | $277,500 | ||
Sale | BENKOWITZ MICHAEL officer: PRESIDEN.. | Common Stock | 215 | $364.92 | $78,457 | ||
Sale | BENKOWITZ MICHAEL officer: PRESIDEN.. | Common Stock | 1,300 | $367.73 | $478,052 | ||
Sale | BENKOWITZ MICHAEL officer: PRESIDEN.. | Common Stock | 2,700 | $368.29 | $994,370 | ||
Sale | BENKOWITZ MICHAEL officer: PRESIDEN.. | Common Stock | 607 | $368.48 | $223,664 | ||
Sale | BENKOWITZ MICHAEL officer: PRESIDEN.. | Common Stock | 100 | $370.75 | $37,075 | ||
Sale | BENKOWITZ MICHAEL officer: PRESIDEN.. | Common Stock | 178 | $371.57 | $66,139 | ||
Option | BENKOWITZ MICHAEL officer: PRESIDEN.. | Stock Options | 4,500 | $102.11 | $459,495 | ||
Sale | BENKOWITZ MICHAEL officer: PRESIDEN.. | Common Stock | 926 | $366.27 | $339,167 | ||
Option | BENKOWITZ MICHAEL officer: PRESIDEN.. | Common Stock | 4,500 | $102.11 | $459,495 |
| Patent |
|---|
Application Filling date: 2 Mar 2022 Issue date: 8 Sep 2022 |
Application Filling date: 29 Mar 2022 Issue date: 14 Jul 2022 |
Application Filling date: 17 Jan 2022 Issue date: 7 Jul 2022 |
Grant Filling date: 15 Jul 2020 Issue date: 5 Jul 2022 |
Grant Filling date: 27 Sep 2021 Issue date: 14 Jun 2022 |
Application Filling date: 31 Jan 2022 Issue date: 19 May 2022 |
Grant Filling date: 6 Oct 2021 Issue date: 5 Apr 2022 |
Application Filling date: 8 Sep 2021 Issue date: 3 Mar 2022 |
Grant Utility: Salts of treprostinil Filling date: 30 Nov 2020 Issue date: 1 Feb 2022 |
Application Filling date: 6 Oct 2021 Issue date: 27 Jan 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 21 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
United Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying Stock
Insmed: Company Presses On With Further POC PAH Treatment Data
MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition
Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month
The Zen Ten - My Top Picks For 2025
United Therapeutics: Exciting Company With A Big Problem
3D Systems Corp Faces A 2030 Feast-Or-Famine Scenario
Liquidia Continues To Expand Their Growth Vs. MannKind's Growth In Share Prices
-
What's the price of United Therapeutics stock today?
One share of United Therapeutics stock can currently be purchased for approximately $313.22.
-
When is United Therapeutics's next earnings date?
Unfortunately, United Therapeutics's (UTHR) next earnings date is currently unknown.
-
Does United Therapeutics pay dividends?
No, United Therapeutics does not pay dividends.
-
How much money does United Therapeutics make?
United Therapeutics has a market capitalization of 16.07B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 20.2% to 2.33B US dollars.
-
What is United Therapeutics's stock symbol?
United Therapeutics Corporation is traded on the NASDAQ under the ticker symbol "UTHR".
-
What is United Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of United Therapeutics?
Shares of United Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are United Therapeutics's key executives?
United Therapeutics's management team includes the following people:
- Dr. Martine A. Rothblatt Founder, Chairman & Chief Executive Officer(age: 70, pay: $3,240,000)
- Mr. Michael I. Benkowitz Pres & Chief Operating Officer(age: 53, pay: $1,960,000)
- Mr. Paul A. Mahon Executive Vice President, Gen. Counsel & Corporation Sec.(age: 61, pay: $1,670,000)
- Mr. James C. Edgemond Chief Financial Officer & Treasurer(age: 57, pay: $1,420,000)
-
Is United Therapeutics founder-led company?
Yes, United Therapeutics is a company led by its founder Dr. Martine A. Rothblatt.
-
How many employees does United Therapeutics have?
As Jul 2024, United Therapeutics employs 1,168 workers.
-
When United Therapeutics went public?
United Therapeutics Corporation is publicly traded company for more then 26 years since IPO on 17 Jun 1999.
-
What is United Therapeutics's official website?
The official website for United Therapeutics is unither.com.
-
Where are United Therapeutics's headquarters?
United Therapeutics is headquartered at 1040 Spring Street, Silver Spring, MD.
-
How can i contact United Therapeutics?
United Therapeutics's mailing address is 1040 Spring Street, Silver Spring, MD and company can be reached via phone at +30 16089292.
-
What is United Therapeutics stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for United Therapeutics in the last 12 months, the avarage price target is $458. The average price target represents a 46.22% change from the last price of $313.22.
United Therapeutics company profile:
United Therapeutics Corporation
unither.comExchange:
NASDAQ
Full time employees:
1,168
Industry:
Biotechnology
Sector:
Healthcare
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
1040 Spring Street
Silver Spring, MD 20910
Silver Spring, MD 20910
CIK: 0001082554
ISIN: US91307C1027
CUSIP: 91307C102
